A dose-finding study of duloxetine based on serotonin transporter occupancy
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Rationale Positron emission tomography (PET) has been utilized for determining the dosage of antipsychotic drugs. To evaluate the dosage of antidepressants such as selective serotonin reuptake inhibitors, serotonin transporter occupancy (5-HTT) is also a useful index.Objectives We investigated the degree of 5-HTT occupancy with different doses of the antidepressant duloxetine and the time-course of 5-HTT occupancy using PET.Methods PET scans with [11C]DASB were performed before and after a single administration of duloxetine (5-60 mg), and three consecutive scans were performed after a single dose or repeated doses of 60 mg of duloxetine.Results 5-HTT occupancies by duloxetine were increased by 35.3 to 86.5% with dose and plasma concentration increments. The ED50 value of 5-HTT occupancy was 7.9 mg for dose and 3.7 ng/ml for plasma concentration. In the time-course of 5-HTT occupancy, mean occupancies were 81.8% at 6 h, 71.9% at 25 h, and 44.9% at 53 h after a single administration, and 84.3% at 6 h, 71.9% at 49 h, and 47.1% at 78 h after repeated administrations.Conclusions Based on 5-HTT occupancy, 40 mg and more of duloxetine was needed to attain 80% occupancy, and 60 mg of duloxetine could maintain a high level of 5-HTT occupancy with a once-a-day administration schedule.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ED50 values in mg were 3·4 for citalopram [17], 9·1 for sertraline [17], 5 for paroxetine [17], 2·7 for fluoxetine [17], 5·8 for venlafaxine [17], 7·9 for duloxetine [40], 8·5 for vortioxetine [42], and 14·4 for desvenlafaxine [33].”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [40]
In the citing paper
“Eight studies excluded participants taking other possibly interacting medications (e.g., other psychotropic drugs or substances with high affinity for SERT) [19, 31, 32, 37–40, 42].”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [40]
In the citing paper
“One study reported overall alcohol consumption during the study period [35], and seven studies controlled for present or past alcohol problems or abuse [17, 28, 30, 33, 34, 39, 40].”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [40]
In the citing paper
“Five of 17 studies included non-smokers only, while the remaining studies did not mention smoking status [19, 30, 35, 39, 40].”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [40]
In the citing paper
“Five studies provided data on the time-course of SERT occupancy as it decreases over time after a single dose [30, 35, 39, 40] or repeated (7–10 days) [36, 40] administration of antidepressants in healthy volunteers.”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [40]
Citations
Cites
Bymaster, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00298-6 · Cited by 717 · cited 1×
“An in vitro report indicated that duloxetine has greater affinity to 5-HTT (Ki=0.8) than to noradrenaline transporter (Ki=7.5)(Bymaster et al. 2001).”
BackgroundInfluentialCentral D2-Dopamine Receptor Occupancy in Schizophrenic Patients Treated With Antipsychotic Drugs
Farde, L. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800250087012 · Cited by 692 · cited 1×
“Positron emission tomography (PET) studies have made it possible to investigate the in vivo neurotransmission in the living human brain (Farde et al. 1988).”
BackgroundIchise, M., Liow, J.-S., Lu, J.-Q., Takano, A., Model, K., Toyama, H., Suhara, T., Suzuki, K., Innis, R. B., & Carson, R. E. (2003) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000085441.37552.ca · Cited by 650 · cited 2×
“Quantification was performed using multilinear reference tissue model 2 (Ichise et al. 2003), which was originally developed based on [11C]DASB data.”
MethodSelf-citationMeyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517 · cited 8×
“5-HTT occupancy was reported to be over 80% at clinical doses of antidepressants such as SSRIs and tricyclic ones during the treatment of depression ( Meyer et al. 2001, 2004 ; S uhara et al.2003).”
BackgroundMethodInfluentialDetke, M. J., Lu, Y., Goldstein, D. J., Hayes, J. R., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0407 · Cited by 384 · cited 3×
“…/day (60 mg b.i.d.) of duloxetine were reported to show efficacy for major depressive disorder (Goldstein et al. 2002; Detke et al. 2004), and a dose of 60 mg a day was also shown to have a clinical effect in the treatment of major depressive disorder (Brannan et al. 2005a,b; Detke et al. 2002a,b).”
BackgroundMethodMeyer, J. H., Wilson, A. A., Ginovart, N., Goulding, V., Hussey, D., Hood, K., & Houle, S. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1843 · Cited by 340 · cited 6×
“5-HTT occupancy was reported to be over 80% at clinical doses of antidepressants such as SSRIs and tricyclic ones during the treatment of depression ( Meyer et al. 2001, 2004 ; S uhara et al.2003).”
BackgroundInfluentialDuloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial
Goldstein, D. J., Mallinckrodt, C., Lu, Y., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0309 · Cited by 334 · cited 3×
“Eighty milligrams/day (40 mg b.i.d.) and 120 mg /day (60 mg b.i.d.) of duloxetine were reported to show efficacy for major depressive disorder (Goldstein et al. 2002; Detke et al. 2004), and a dose of 60 mg a day was also shown to have a clinical effect in the treatment of major depressive disorder…”
BackgroundDetke, M. J., Wiltse, C. G., Mallinckrodt, C. H., McNamara, R. K., Demitrack, M. A., & Bitter, I. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.01.002 · Cited by 282 · cited 3×
“…(40 mg b.i.d.) and 120 mg /day (60 mg b.i.d.) of duloxetine were reported to show efficacy for major depressive disorder (Goldstein et al. 2002; Detke et al. 2004), and a dose of 60 mg a day was also shown to have a clinical effect in the treatment of major depressive disorder (Brannan et al.…”
BackgroundDuloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression
Detke, M. J., Lu, Y., Goldstein, D. J., McNamara, R. K., & Demitrack, M. A. (2002) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00060-2 · Cited by 279 · cited 6×
“Eighty milligrams/day (40 mg b.i.d.) and 120 mg /day (60 mg b.i.d.) of duloxetine were reported to show efficacy for major depressive disorder (Goldstein et al. 2002; Detke et al. 2004), and a dose of 60 mg a day was also shown to have a clinical effect in the treatment of major depressive disorder (Brannan et al. 200…”
BackgroundMethodInfluentialHoule, S., Ginovart, N., Hussey, D., Meyer, J. H., & Wilson, A. A. (2000) · European Journal of Nuclear Medicine · doi:10.1007/s002590000365 · Cited by 276 · cited 1×
“In this study, the thalamus was used to measure 5-HTT occupancy because it has the highest specific binding in the brain (Houle et al. 2000).”
Method
Cited by
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K., Fric, M., Gerlach, M., Greiner, C., Gründer, G., et al. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1286287 · Cited by 868
Meyer, J. H. (2007) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0709 · Cited by 272
Duloxetine: Clinical Pharmacokinetics and Drug Interactions
Knadler, M. P., Lobo, E., Chappell, J., & Bergstrom, R. (2011) · Clinical Pharmacokinetics · doi:10.2165/11539240-000000000-00000 · Cited by 237
5‐HT radioligands for human brain imaging with PET and SPECT
Paterson, L. M., Kornum, B. R., Nutt, D. J., Pike, V. W., & Knudsen, G. M. (2013) · Medicinal Research Reviews · doi:10.1002/med.20245 · Cited by 151
Metadata
- Authors
- Takano, A., Suzuki, K., Kosaka, J., Ota, M., Nozaki, S., Ikoma, Y., Tanada, S., & Suhara, T.
- Affiliations
- National Institute of Radiological Sciences (JP)
- Corresponding author
- Suhara, Tetsuya
- Venue
- Psychopharmacology
- Published
- 2006-02-28
- Volume
- 185
- Issue
- 3
- Pages
- 395-399
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W1989915234
- Cited by
- 110
- References
- 28
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 2 · 2022: 1 · 2021: 5 · 2020: 3 · 2019: 5 · 2018: 2 · 2017: 5 · 2016: 2 · 2015: 7 · 2014: 6 · 2013: 11 · 2012: 9
- FWCI
- 6.23
- Type
- journal article
- Language
- en
- Open access
- green
- repo.qst.go.jp
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- Funders
- Shionogi
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- duloxetine, dose-finding, [11C]DASB, positron emission tomography, selective serotonin reuptake inhibitors, antidepressants, plasma concentration, once-daily dosing, ED50
- MeSH terms
- Duloxetine Hydrochloride, Adult, Dose-Response Relationship, Drug, Humans, Magnetic Resonance Imaging, Male, Thiophenes, Selective Serotonin Reuptake Inhibitors, Positron-Emission Tomography, Serotonin Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A dose-finding study of duloxetine based on serotonin transporter occupancy. https://app.cochat.ai/papers/10.1007/s00213-005-0304-0
- The paper
- Takano, A., Suzuki, K., Kosaka, J., Ota, M., Nozaki, S., Ikoma, Y., Tanada, S., & Suhara, T. (2006). A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology. https://doi.org/10.1007/s00213-005-0304-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.